<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083901</url>
  </required_header>
  <id_info>
    <org_study_id>06-0343</org_study_id>
    <secondary_id>R21AG027809</secondary_id>
    <nct_id>NCT01083901</nct_id>
  </id_info>
  <brief_title>Acetaminophen and Impaired Musculoskeletal Adaptations to Exercise Training</brief_title>
  <official_title>Acetaminophen and Impaired Musculoskeletal Adaptations to Exercise Training</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if taking the pain reliever acetaminophen (ACET)
      interferes with some of the benefits of weight lifting on muscles and bone density in older
      men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The commonly used pain relievers acetaminophen and ibuprofen may impair musculoskeletal
      adaptations to progressive resistance exercise training by inhibiting exercise-induced muscle
      protein synthesis.

      To test the hypothesis that acetaminophen and ibuprofen would diminish training-induced
      increases in fat-free mass, untrained men (n=26) aged â‰¥ 50 years participated in 16 weeks of
      high-intensity progressive resistance exercise training and bone-loading exercises and were
      randomly assigned to take ACET (1000 mg), ibuprofen (400 mg) or placebo 2 hours before each
      exercise session.

      The primary outcome was the change in total body fat-free mass measured by dual-energy X-ray
      absorptiometry (DXA) at baseline and week 16. Our primary interest was in the comparison of
      the acetaminophen and placebo groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Body Fat-free Mass</measure>
    <time_frame>16 weeks</time_frame>
    <description>change from baseline to 16 weeks in fat-free mass measured by DXA (Hologic Discovery W, version 12.6)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total Body Fat Mass</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change from baseline to 16 weeks in total body fat mass.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Upper Body Strength.</measure>
    <time_frame>16 weeks</time_frame>
    <description>Strength was measured using the one-repetition maximum method. Upper body strength was a composite of bench press, overhead press, seated row, and lateral pull-down strength.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lower Body Strength</measure>
    <time_frame>16 weeks</time_frame>
    <description>Strength was measured using the one-repetition maximum method. Lower body strength was a composite of knee flexion, knee extension, and leg press strength.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Osteoporosis</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Resistance training with Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetaminophen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resistance Training with ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibuprofen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Resistance training</intervention_name>
    <description>high intensity progressive resistance exercise training</description>
    <arm_group_label>Resistance training with Acetaminophen</arm_group_label>
    <arm_group_label>Resistance Training with ibuprofen</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  average use of acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs)
             [including aspirin] less than 3 days per month

          -  not currently engaged in moderate-to-vigorous weight-lifting exercise

          -  non-smoker

          -  willing to participate in a supervised exercise program for 9 months

        Exclusion Criteria:

          -  relative or absolute contraindications to regular use of acetaminophen or NSAIDs
             including known allergy or intolerance to either drug,history of peptic ulcer or GI
             bleeding, anemia, asthma with bronchospasm induced by aspirin or other NSAIDS,
             moderate or severe renal impairment, known hepatobiliary disease

          -  contraindications to exercise testing and training including congestive heart failure
             class III or IV, uncontrolled hypertension and unstable cardiovascular disease

          -  thyroid dysfunction

          -  orthopedic problems that limit the ability to perform vigorous exercise or increase
             the likelihood of the use of pain medications

          -  drugs known to alter bone metabolism

          -  allergy to lidocaine

          -  diabetes mellitus requiring pharmacologic therapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Jankowski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2010</study_first_submitted>
  <study_first_submitted_qc>March 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <results_first_submitted>February 4, 2013</results_first_submitted>
  <results_first_submitted_qc>February 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 8, 2013</results_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from Dec 2006 to Jan 2010. They were recruited from the greater Denver area using advertisements.</recruitment_details>
      <pre_assignment_details>Volunteers who did not meet inclusion criteria were excluded from the study during the initial screening visits prior to randomization to the study arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acetaminophen and Resistance Exercise</title>
          <description>Progressive resistance exercise training and bone-loading exercise on up to 6 days per week and administration of acetaminophen, 1000 mg, taken 2 hours before exercise on exercise days for up to 36 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Ibuprofen and Resistance Exercise</title>
          <description>Progressive resistance exercise training and bone-loading exercise on up to 6 days per week and administration of acetaminophen, 400 mg, taken 2 hours before exercise on exercise days for up to 36 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo and Resistance Exercise</title>
          <description>Progressive resistance exercise training and bone-loading exercise on up to 6 days per week and placebo pills (matching active study drug) taken 2 hours before exercise on exercise days for up to 36 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acetaminophen and Resistance Exercise</title>
          <description>Progressive resistance exercise training and bone-loading exercise on up to 6 days per week and administration of acetaminophen, 1000 mg, taken 2 hours before exercise on exercise days for up to 36 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Ibuprofen and Resistance Exercise</title>
          <description>Progressive resistance exercise training and bone-loading exercise on up to 6 days per week and administration of acetaminophen, 400 mg, taken 2 hours before exercise on exercise days for up to 36 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo and Resistance Exercise</title>
          <description>Progressive resistance exercise training and bone-loading exercise on up to 6 days per week and placebo pills (matching active study drug) taken 2 hours before exercise on exercise days for up to 36 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="5"/>
                    <measurement group_id="B2" value="58" spread="6"/>
                    <measurement group_id="B3" value="62" spread="7"/>
                    <measurement group_id="B4" value="61" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181" spread="8"/>
                    <measurement group_id="B2" value="178" spread="10"/>
                    <measurement group_id="B3" value="176" spread="7"/>
                    <measurement group_id="B4" value="178" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94.5" spread="16.6"/>
                    <measurement group_id="B2" value="89.3" spread="12.5"/>
                    <measurement group_id="B3" value="87.9" spread="18.0"/>
                    <measurement group_id="B4" value="90.4" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fat-free mass</title>
          <description>Total body fat-free mass measured by DXA (Hologic Discovery W, version 12.6)</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="6.1"/>
                    <measurement group_id="B2" value="63.5" spread="8.2"/>
                    <measurement group_id="B3" value="62.7" spread="9.1"/>
                    <measurement group_id="B4" value="63.4" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fat mass</title>
          <description>Total body fat mass measured by DXA (Hologic Discovery W, version 12.6)</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.3" spread="12.6"/>
                    <measurement group_id="B2" value="25.8" spread="5.3"/>
                    <measurement group_id="B3" value="25.2" spread="9.6"/>
                    <measurement group_id="B4" value="27.0" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Body Fat-free Mass</title>
        <description>change from baseline to 16 weeks in fat-free mass measured by DXA (Hologic Discovery W, version 12.6)</description>
        <time_frame>16 weeks</time_frame>
        <population>All participants with baseline and 16 week data were included in the analysis (i.e., intention-to-treat).</population>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen and Resistance Exercise Training</title>
          </group>
          <group group_id="O2">
            <title>Ibuprofen and Resistance Exercise Training</title>
          </group>
          <group group_id="O3">
            <title>Placebo and Resistance Exercise Training</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Body Fat-free Mass</title>
          <description>change from baseline to 16 weeks in fat-free mass measured by DXA (Hologic Discovery W, version 12.6)</description>
          <population>All participants with baseline and 16 week data were included in the analysis (i.e., intention-to-treat).</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.6"/>
                    <measurement group_id="O2" value="2.3" spread="0.9"/>
                    <measurement group_id="O3" value="0.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that the changes in total body fat-free mass in response to resistance exercise training would not be different among the groups. The expected difference in fat-free mass between the Acetaminophen and Placebo groups was 1.8 +/- 1.0% with a 3.6 +/1 1.0% increase in fat-free mass in the Placebo group. The study was designed to achieve 96% power at the 0.05 level with 10 men in the acetaminophen and placebo groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>ANCOVA</method>
            <method_desc>Changes from baseline to 16 weeks were regressed on the baseline measurement.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Body Fat Mass</title>
        <description>Change from baseline to 16 weeks in total body fat mass.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen and Resistance Exercise Training</title>
          </group>
          <group group_id="O2">
            <title>Ibuprofen and Resistance Exercise Training</title>
          </group>
          <group group_id="O3">
            <title>Placebo and Resistance Exercise Training</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Body Fat Mass</title>
          <description>Change from baseline to 16 weeks in total body fat mass.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.6"/>
                    <measurement group_id="O2" value="-1.4" spread="0.9"/>
                    <measurement group_id="O3" value="-0.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>ANCOVA</method>
            <method_desc>The change in fat mass was regressed on the baseline measure.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Upper Body Strength.</title>
        <description>Strength was measured using the one-repetition maximum method. Upper body strength was a composite of bench press, overhead press, seated row, and lateral pull-down strength.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen and Resistance Exercise Training</title>
          </group>
          <group group_id="O2">
            <title>Ibuprofen and Resistance Exercise Training</title>
          </group>
          <group group_id="O3">
            <title>Placebo and Resistance Exercise Training</title>
          </group>
        </group_list>
        <measure>
          <title>Changes in Upper Body Strength.</title>
          <description>Strength was measured using the one-repetition maximum method. Upper body strength was a composite of bench press, overhead press, seated row, and lateral pull-down strength.</description>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="5.5"/>
                    <measurement group_id="O2" value="35.2" spread="8.6"/>
                    <measurement group_id="O3" value="26.5" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>ANCOVA</method>
            <method_desc>Change in strength was regressed on baseline measures.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lower Body Strength</title>
        <description>Strength was measured using the one-repetition maximum method. Lower body strength was a composite of knee flexion, knee extension, and leg press strength.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen and Resistance Exercise Training</title>
          </group>
          <group group_id="O2">
            <title>Ibuprofen and Resistance Exercise Training</title>
          </group>
          <group group_id="O3">
            <title>Placebo and Resistance Exercise Training</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Lower Body Strength</title>
          <description>Strength was measured using the one-repetition maximum method. Lower body strength was a composite of knee flexion, knee extension, and leg press strength.</description>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" spread="9.4"/>
                    <measurement group_id="O2" value="40.8" spread="14.6"/>
                    <measurement group_id="O3" value="18.0" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>ANCOVA</method>
            <method_desc>Changes in strength were regressed on the baseline measure.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Acetaminophen and Resistance Exercise Training</title>
        </group>
        <group group_id="E2">
          <title>Ibuprofen and Resistance Exercise Traininig</title>
        </group>
        <group group_id="E3">
          <title>Placebo and Resistance Exercise Training</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a preliminary study that was limited by small sample size, exclusion of women, and the duration of intervention which was too brief to measure changes in bone mineral density.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Catherine M. Jankowski</name_or_title>
      <organization>University of Colorado Denver</organization>
      <phone>303-724-7383</phone>
      <email>catherine.jankowski@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

